Amneal receives approval for generic tobradex®

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) today announced that it has received abbreviated new drug application (anda) approval from the u.s. food and drug administration (fda) for the generic version of tobradex®, which adds another complex ophthalmic product to the generics portfolio. dexamethasone and tobramycin ophthalmic suspension 0.3%/0.1% is the generic version of tobradex®, which is indicated for steroid-responsive inflamm
AMRX Ratings Summary
AMRX Quant Ranking